Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimlovisertib and Ritlecitinib in Rheumatoid Arthritis
NCT04413617Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of zimlovisertib, ritlecitinib tosilate in rheumatoid arthritis (RA), sponsored by Pfizer. Started Jul 2020; status: completed.
02
Drugs
zimlovisertibritlecitinib tosilate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04413617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413617.